Advertisement
Singapore markets close in 39 minutes
  • Straits Times Index

    3,325.47
    -0.81 (-0.02%)
     
  • Nikkei

    39,667.07
    +493.92 (+1.26%)
     
  • Hang Seng

    18,093.37
    +20.47 (+0.11%)
     
  • FTSE 100

    8,298.63
    +50.84 (+0.62%)
     
  • Bitcoin USD

    61,461.91
    +620.35 (+1.02%)
     
  • CMC Crypto 200

    1,280.51
    -3.27 (-0.25%)
     
  • S&P 500

    5,469.30
    +21.43 (+0.39%)
     
  • Dow

    39,112.16
    -299.05 (-0.76%)
     
  • Nasdaq

    17,717.65
    +220.84 (+1.26%)
     
  • Gold

    2,325.50
    -5.30 (-0.23%)
     
  • Crude Oil

    80.99
    +0.16 (+0.20%)
     
  • 10-Yr Bond

    4.2380
    -0.0100 (-0.24%)
     
  • FTSE Bursa Malaysia

    1,588.47
    +3.09 (+0.19%)
     
  • Jakarta Composite Index

    6,909.25
    +26.55 (+0.39%)
     
  • PSE Index

    6,313.11
    +14.06 (+0.22%)
     

Atossa to Present at the Sidoti Small-Cap Investor Conference

Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc.

SEATTLE, June 05, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the Company will present at the Sidoti Small-Cap Investor Conference being held June 12-13, 2024. The presentation by Steven Quay, M.D., Ph.D., Atossa’s President and Chief Executive Officer, will take place on Thursday, June 13 at 9:15 am eastern time. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

To register and view a live webcast of the presentation, please visit the event's website at: https://sidoti.zoom.us/webinar/register/WN_MB9PZN5rTjeg5vMpcE82Gg

Following the conference, a recording of the webcast will be made available on the investor relations page of Atossa’s website: https://investors.atossatherapeutics.com/

ADVERTISEMENT

About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. For more information, please visit www.atossatherapeutics.com.

Contact:
Eric Van Zanten
VP, Investor and Public Relations
610-529-6219
eric.vanzanten@atossainc.com